As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Anaptysbio, Inc. The largest reported stake is Sirenia Capital Management LP's, at 5%. 12 filings are on record since July 29, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Anaptysbio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 1,491,959 · Sole dispositive: 0 · Shared dispositive: 1,491,959 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 55,303 · Sole dispositive: 0 · Shared dispositive: 55,303 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Sirenia Capital Management LP · Percent: 6.7% · SCHEDULE 13G
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Holder: Morgan Stanley · Percent: 3.6% · SCHEDULE 13G/A
Anaptysbio, Inc has 12 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Sirenia Capital Management LP | 5% | 1,491,959 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| The Goldman Sachs Group, Inc. | 4.5% | 1,251,295 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| 3.6% | 1,006,063 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 | |
| 3.12% | 864,618 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| Millennium Management LLC | 2.9% | 813,571 | SCHEDULE 13G/A, 2026-01-16 | 2025-12-31 |
| Point72 Asset Management, L.P. | 0.2% | 55,303 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Anaptysbio, Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Anaptysbio, Inc and the records around it.
Anaptysbio, Inc elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), CYBIN INC. (Aug 2026), Design Therapeutics, Inc. (Aug 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Watch Anaptysbio, Inc
Get an email when Anaptysbio, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Anaptysbio, Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Anaptysbio, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anaptysbio, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Sirenia Capital Management LP | 0 | 1,491,959 | 0 | 1,491,959 | SCHEDULE 13G/A, 2026-08-14 |
| Alex Silverstein | 0 | 1,491,959 | 0 | 1,491,959 | SCHEDULE 13G/A, 2026-08-14 |
| Point72 Asset Management, L.P. | 0 | 55,303 | 0 | 55,303 | SCHEDULE 13G/A, 2026-05-15 |
| Point72 Capital Advisors, Inc. | 0 | 55,303 | 0 | 55,303 | SCHEDULE 13G/A, 2026-05-15 |
| Steven A. Cohen | 0 | 55,303 | 0 | 55,303 | SCHEDULE 13G/A, 2026-05-15 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies Anaptysbio, Inc by CUSIP 032724106 and gives its principal executive office as 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA 92121 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 5.23% | SCHEDULE 13G |
| 2025-08-05 | Morgan Stanley | 6.3% | SCHEDULE 13G |
| 2025-08-07 | Mathew P. Arens | 7.71% | SCHEDULE 13G/A |
| 2025-09-23 | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2025-11-12 | The Goldman Sachs Group, Inc. | 4.5% | SCHEDULE 13G/A |
| 2025-11-14 | Mathew P. Arens | 3.12% | SCHEDULE 13G/A |
| 2026-01-16 | Millennium Management LLC | 2.9% | SCHEDULE 13G/A |
| 2026-02-11 | Morgan Stanley | 3.6% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Sirenia Capital Management LP | 6.7% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 0.2% | SCHEDULE 13G/A |
| 2026-08-14 | Sirenia Capital Management LP | 5% | SCHEDULE 13G/A |
Questions about who owns Anaptysbio, Inc
Who owns Anaptysbio, Inc?
On this page, one holder's latest ownership filing reports 5% or more of Anaptysbio, Inc: Sirenia Capital Management LP (5%, Schedule 13G/A, filed 2026-08-14).
When did Sirenia Capital Management LP buy into Anaptysbio, Inc?
The filings give report dates, not purchase dates. The earliest filing from Sirenia Capital Management LP on this page is the Schedule 13G, filed 2026-05-15, reporting 6.7%; its latest, Schedule 13G/A filed 2026-08-14, reports 5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Anaptysbio, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 11, 2026 | Leadership change: Christopher M. Murphy appointed, Chief Financial Officer, and 2 more | — | Leadership changes | Source |
| April 20, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Anaptysbio, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.